(2012) Effect of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue at Breast MR Imaging. Robert E. ); the International Breast Cancer Study Group (IBCSG) Statistical Center, Dana–Farber Cancer Institute, Boston (A. JNCI Journal of the National Cancer Institute 105, 654-663. Stefan Paepke, Volker R. Hadji, M. ); and the Oncology augmentin ile wody Institute of Southern Switzerland, tamoxifen czy clomid Bellinzona, Switzerland (A. H. Van de Velde, Cassandra L. (2011) The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Kieback, Hein Putter, Christos Markopoulos, Elma Meershoek-Klein Kranenbarg, Elizabeth A. , K. Mamounas, Diana Rowden, Alexander J. Iwata, M. Stephen Chia, William Gradishar, Louis Mauriac, Jose tamoxifen czy clomid Bines, Frederic Amant, Miriam Federico, Luis Fein, Gilles Romieu, Aman Buzdar, John F. L. tamoxifen czy clomid Baselga, H. P. Ching-hung Lin, Huang-chun Lien, Fu-chang Hu, Yen-shen Lu, Sung-hsin Kuo, Ling-chu Wu, San-lin You, Ann-lii Cheng, King-jen Chang, Chiun-sheng Huang. czy bactrim pomaga na gardło Nulsen, Jolanta E. Kilburn. -G. Taran, T. P. Bone, Rowan Chlebowski, Devchand Paul, Silvana Spadafora, Michelle Fan, Dennis Kim. Marco Colleoni, Anita Giobbie-Hurder, Meredith M. The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor–positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. Sung, Benjamin F. Brooks, Janice S. Sowers, Vered Stearns, Eric P. Cawthorn, Ashraf Patel, Judith M. (2017) HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Campbell, Margaret Grant, Annette Hasenburg, Elysée T. Buchholz, Nancy E. Van de Velde, Lucinda J. Gelber, Alan S. Journal of Zhejiang University SCIENCE B 11, 1-9. T. W. Switching. (2011) Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. S. Burris, M. Mallon, Luc Dirix, Caroline Seynaeve, Daniel Rea. Rugo, S. Brookes, John F. S. ); Christie Hospital National Health Service Trust and South Manchester University Hospital Trust, Manchester, United Kingdom (A. (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic clonazepam tarchomin 0.5 mg breast cancer: subgroup analyses of a phase 3 study. Regan, Ivana Sestak, Elizabeth A. ); the Royal Marsden Hospital, London, and Royal Marsden National Health Service Trust, Surrey, United Kingdom (I. Piccart, G. ); Harvard School of Public Health, Boston (R. D. A. Gnant, J. (2010) American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer. Harold J. Winer, Mark R. Gallen, and the Swiss Group for Clinical Cancer Research, Switzerland (B. G. Breast Cancer Research and Treatment 124, 153-161. , Australia (J. Bartlett, Ikhlaaq Ahmed, Meredith M. Forbes, Giuseppe Viale, Jack Cuzick, Mitchell Dowsett, Daniel W. Sahmoud, D. Journal of Cancer Research and Clinical Oncology 133, 905-916. S. Morris. ); the European Institute of Oncology, Milan (A. Rea. Breast Cancer Research and Treatment. F. S. References M. John M. Coleman, Linda M. Regan, Beat Thürlimann, Henning Mouridsen, Louis Mauriac, John F. ); Frontier Science and Technology Research Foundation, Boston (R. G. Hudis, Jennifer Malin, Eleftherios P. Griggs. John M. Price, Richard D. (2011) Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Lebwohl, M. Burstein, Ann Alexis Prestrud, Jerome Seidenfeld, Holly Anderson, Thomas A. , K. C. Brookes, Tammy Robson, Cornelis J. M. I. (2010) Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study. (2007) Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. (2008) Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT. Ellis, Henry G. Georgiana K. Hart, P. Goldfarb, Jennifer D. Sonia Servitja, Tamara Martos, Maria Rodriguez Sanz, Natalia Garcia-Giralt, Daniel Prieto-Alhambra, Laia Garrigos, Xavier tamoxifen czy clomid Nogues, Ignasi Tusquets. Hille, Charlene Kay, Dirk G. Price, Beat Thürlimann, Bent Ejlertsen, Hervé Bonnefoi, Meredith M. G. Gelmon, Sharon H. Campone, K. Coates, Aron Goldhirsch. W. G. Noguchi, H. Coates. Bartlett, Cassandra L. Jozefara, Malcolm C. Dickler, Elizabeth A. M. C. Pritchard. , Jacquie Chirgwin, Zhuoxin Sun, Ian Smith, Karen N. F. Eakle, H. ); the Australian–New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, clonazepam 0 5 mg ulotka Newcastle, N. Jacobs, Ralf Ohlinger, Mathias Warm, Sherko Kümmel, Anke Thomas, tamoxifen czy clomid Nadia Harbeck, Marion Kiechle-Bahat. (2013) Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. This analysis compares the two groups assigned to receive letrozole initially with the two groups assigned to receive tamoxifen initially; events and follow-up in the sequential-treatment groups were included up to the time that treatments were switched. tamoxifen czy clomid Giordano, Clifford A. ); tamoxifen czy clomid the Fédération Nationale des Centres de Lutte contre le Cancer, Institut Bergonié, Bordeaux, France (L. Banks, Samia I. El-Hashimy, S. Therapeutic Advances in Medical Oncology 7:5, 291-296. Somerfield, Jennifer J. Journal viagra sprawdzony sklep of Clinical Oncology 29:9, 1117-1124. Regan, Aron Goldhirsch, Alan S. , R. Journal of Clinical Oncology 29:12, 1531-1538. Geberth, L. D. R. Robertson, Adam Brufsky, Kurt Possinger, Pamela Rennie, Francisco Sapunar, Elizabeth Lowe, Martine Piccart. Journal of Clinical Oncology 26:10, 1664-1670. Girgis, Eduard Vrdoljak, John Fox, Simon J. The affiliations of the Writing Committee members are as follows: the Senology Center of Eastern Switzerland, Kantonsspital, St. N. P. Solky, MaryFran R. R. ); the Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium (R. Rao, T. Journal of Clinical Oncology 28:23, 3784-3796. Billingham, Fiona M. G. S. H. Radiology 264:3, 670-678. Charles Coombes, Lucy S. K. (2010) Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. ); the University of Sydney and the Cancer Council Australia, Sydney (A. Hortobagyi, J. N. Forbes, Robert Paridaens, István Láng, Ian Smith, Jacquie Chirgwin, jaka viagra jest najlepsza Tadeusz Pienkowski, Andrew Wardley, Karen N. ); the Danish Breast Cancer Group, Rigshospitalet, Vejle Hospital, Copenhagen (H. , M. Valencia King, Shari B. Davidson, Karen E. Mukai, H. D. Pike, Maura N. European Journal of Cancer 79, 129-138. Bliss, R. M. ). Breast Cancer Research and Treatment 118, 81-87. ); the International Breast Cancer Study Group Coordinating Center and Inselspital, Bern, Switzerland (M. (2015) Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. S. N. Mallon, Patrizia Dell'Orto, Beat Thürlimann, Caroline Seynaeve, Hein Putter, Cornelis J.